Literature DB >> 2441780

"Spontaneous" complete remissions in chronic lymphocytic leukemia: report of three cases and review of the literature.

J M Ribera, N Viñolas, A Urbano-Ispizua, T Gallart, E Montserrat, C Rozman.   

Abstract

"Spontaneous" complete remissions (SCR) are a rare event in chronic lymphocytic leukemia (CLL). In this article, we report three cases of SCR observed in a series of 285 patients followed at a single institution during the last 15 years. SCR was documented by clinical and hematologic data, including bone marrow biopsy, and immune cell markers. A delay of 0.9-1.6 years between "clinical" and "clonal" remission was observed. A review of other cases of SCR in CLL is also performed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2441780

Source DB:  PubMed          Journal:  Blood Cells        ISSN: 0340-4684


  7 in total

1.  A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.

Authors:  Davide Bagnara; Matthew S Kaufman; Carlo Calissano; Sonia Marsilio; Piers E M Patten; Rita Simone; Philip Chum; Xiao-Jie Yan; Steven L Allen; Jonathan E Kolitz; Sivasubramanian Baskar; Christoph Rader; Hakan Mellstedt; Hodjattallah Rabbani; Annette Lee; Peter K Gregersen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-03-08       Impact factor: 22.113

2.  HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.

Authors:  Annika Nelde; Daniel J Kowalewski; Linus Backert; Heiko Schuster; Jan-Ole Werner; Reinhild Klein; Oliver Kohlbacher; Lothar Kanz; Helmut R Salih; Hans-Georg Rammensee; Stefan Stevanović; Juliane S Walz
Journal:  Oncoimmunology       Date:  2018-02-14       Impact factor: 8.110

Review 3.  Hodgkin's disease developing after spontaneous remission of chronic lymphocytic leukemia.

Authors:  H H Schmidt; H Sill; M Eibl; C Beham-Schmid; G Höfler; O A Haas; G J Krejs; W Linkesch
Journal:  Ann Hematol       Date:  1995-11       Impact factor: 3.673

4.  Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Timothy G Call; Clive S Zent; Jose F Leis; Betsy LaPlant; Deborah A Bowen; Michelle Roos; Kristina Laumann; Asish K Ghosh; Connie Lesnick; Mao-Jung Lee; Chung S Yang; Diane F Jelinek; Charles Erlichman; Neil E Kay
Journal:  Cancer       Date:  2012-07-03       Impact factor: 6.860

5.  Identification of protamine 1 as a novel cancer-testis antigen in early chronic lymphocytic leukaemia.

Authors:  Farouk Meklat; Yana Zhang; Masum Shahriar; Sharif U Ahmed; Wei Li; Nikolaos Voukkalis; Zhiqing Wang; Jian Zhang; Suhkrob Mastulov; Andrew Jewell; Thomas Giannakouros; Seah H Lim
Journal:  Br J Haematol       Date:  2008-11-22       Impact factor: 6.998

6.  Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia.

Authors:  Annika Nelde; Yacine Maringer; Tatjana Bilich; Helmut R Salih; Malte Roerden; Jonas S Heitmann; Ana Marcu; Jens Bauer; Marian C Neidert; Claudio Denzlinger; Gerald Illerhaus; Walter Erich Aulitzky; Hans-Georg Rammensee; Juliane S Walz
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

7.  Immunopeptidome Diversity in Chronic Lymphocytic Leukemia Identifies Patients with Favorable Disease Outcome.

Authors:  Maddalena Marconato; Yacine Maringer; Juliane S Walz; Annika Nelde; Jonas S Heitmann
Journal:  Cancers (Basel)       Date:  2022-09-25       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.